50,221 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Bought by Jane Street Group LLC

Jane Street Group LLC purchased a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,221 shares of the company’s stock, valued at approximately $265,000. Jane Street Group LLC owned 0.08% of Corvus Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Samlyn Capital LLC grew its stake in Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after purchasing an additional 3,774,658 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter worth $10,855,000. State Street Corp grew its stake in shares of Corvus Pharmaceuticals by 48.2% in the third quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after acquiring an additional 57,943 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Corvus Pharmaceuticals by 64.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after acquiring an additional 53,809 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter worth $136,000. 46.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CRVS shares. Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Oppenheimer increased their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright started coverage on Corvus Pharmaceuticals in a research note on Thursday, January 2nd. They issued a “buy” rating and a $11.00 target price on the stock. Finally, LADENBURG THALM/SH SH increased their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $12.38.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $5.33 on Friday. The company has a market cap of $342.49 million, a P/E ratio of -5.73 and a beta of 1.07. Corvus Pharmaceuticals, Inc. has a 1 year low of $1.30 and a 1 year high of $10.00. The stock’s fifty day moving average price is $7.36 and its 200-day moving average price is $5.42.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.